Health TrialsbyHealthPanel

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Study of ATG-201 in Adult Participants With Autoimmune Diseases

This is a phase I, open-label study of ATG-201 in participants with autoimmune diseases.

Participants needed: 149
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Antengene Biologics LimitedUpdated: Sep 21, 2026Locations: 22
Eligibility criteria

Participants who give consent to this study participation and sign informed cons... [+4]

Intolerance or allergy to the investigational product, or to any component there... [+10]

Read more
Status: Not yet recruiting

A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

This is a randomized, controlled, open-label, multicenter Phase III study to evaluate the efficacy and safety of ATG-022 compared with Investigator's Choice in participants with CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

Participants needed: 380
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Antengene Biologics LimitedUpdated: Aug 31, 2026Locations: 114
Eligibility criteria

Provide signed and dated written informed consent (ICF) before any study-specifi... [+15]

Known active CNS metastases and/or carcinomatous meningitis. [+7]

Read more
Status: Recruiting

A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

This is A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Participants needed: 132
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Antengene Biologics LimitedUpdated: Jul 29, 2026Locations: 30
Eligibility criteria

Provision of signed and dated, written informed consent prior to any study-speci... [+5]

Known active central nervous system metastases and/or carcinomatous meningitis.... [+6]

Read more
Status: Recruiting

A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors

This is an Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients with Advanced/metastatic Solid Tumors

Participants needed: 156
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Antengene Biologics LimitedUpdated: Apr 15, 2026Locations: 22
Eligibility criteria

Provision of signed and dated, written informed consent prior to any study-speci... [+10]

Primary central nervous system disease or central nervous system metastatic dise... [+11]

Read more